Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKTK Essen: Dangerous Merkel cell skin carcinoma exposed

No. 11 | 02/03/2016 | by AM

Merkel cell carcinoma are one of the most dangerous skin carcinoma types. However, the human immune defense system often fails to recognize them as cancer cells. Scientists at the German Cancer Consortium (DKTK) have now found a way to make the tumor visible to the immune system. Present therapies could thereby become a lot more effective. The DKTK brings together the German Cancer Research Center (DKFZ) in Heidelberg with seven partner sites across Germany. This long-term partnership is now eager to implement the results of basic research and to bring on new approaches in prevention, diagnostics and the development of more effective cancer therapies as quickly as possible.

Polyomaviruses trigger various tumor diseases
© Phoebus87, Wikimedia

Merkel cell carcinoma (MCC) is one of the most dangerous skin cancer types because of its ability to grow and frequently metastasize. Around a third of patients diagnosed with MCC will die from the disease. Up to now, this type of skin cancer was relatively rare and affected mainly those patients over 70 years old. But for some years now, it has started to occur more often in the younger population.

The disease is caused by an infection with the Merkel cell polyomavirus. Most viruses including those that trigger cancer, provoke violent immune responses aimed at destroying the infected cells. The Merkel cell carcinoma cells however remain unaffected.

The DKTK scientists at the Essen partner location have now uncovered how Merkel cell carcinoma manage to evade destruction by the immune system, and how to lift their camouflage. The tumor uses so-called epigenetic mechanisms to silence relevant genes of the immune system. Jürgen Becker is the head of the DKTK working group for translational cancer research at the University Hospital in Essen. He explains that 'normally, a viral infection and the conversion into a malignant tumor cell would signal danger and thus activate defense cells. In the re-programmed cancer cells however, the virus removes the histone acetylation process and thus turns off various immune genes. This phenomenon is also known as epigenetic silencing.'

Histones are spherical proteins that wrap our DNA into chromosomes. If the histones are labeled with acetyl groups, this will signal the cell to read the DNA. In Merkel cell carcinoma, the acetyl groups are removed. This in turn switches off a gene of the immune defense that encodes a crucial stress molecule. As a result, the cells of the immune defense, so called T-cells, no longer recognize the tumor and fail to attack.

The scientists from Essen have now succeeded in making the tumor susceptible to the immune response again. They use inhibitors to block the histone deacetylase, which is the key enzyme responsible for the inactivation. As a result, the signal genes are reactivated and can be read again. The scientists were able to show in cell cultures that the treated tumor cells were consequently attacked by specialized T-cells and destroyed.

'We already knew that epigenetic silencing plays a role in cancer. But we were surprised at how central this mechanism is to the escape of the tumor cells', explains Cathrin Ritter, who did this work as part of her thesis at the DKTK. She will probably also be part of the next steps towards clinical trials.

The research team has every reason to be optimistic as this work is extremely interesting for the current immune therapeutics that big pharmaceutical companies are developing. These are based on improving the patients' immune responses. In some patients however, this approach is unsuccessful because the tumor is not even recognized as such. Jürgen Becker is confident that this may change: 'We have managed to show that the epigenetic inactivation of genes is an important camouflage mechanism in Merkel cell carcinoma, and that we can reverse it. We therefore see a good chance to combine current therapies with our results.'

The cooperation within the DKTK alliance has been an important source of inspiration for him. 'As a dermatologist I always have the clinical application in mind. Through networking with basic researchers at the DKTK, I have discovered completely new details that open up new avenues for therapy.'

Ritter C, Fan K, Paulson KG, Nghiem P, Schrama D, Becker JC. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Scientific Reports 2016, DOI:10.1038/srep21678

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS